Advertisement

Clinical Trials for the Evaluation of Sepsis Therapies

  • D. M. Foster
  • G. S. Doig
Conference paper
Part of the Yearbook of Intensive Care and Emergency Medicine book series (YEARBOOK, volume 1997)

Abstract

It is widely acknowledged that sepsis causes substantial morbidity and mortality among the critically ill [1]. Over the years, clinical trials of new therapies for sepsis have failed to find a successful treatment [2–7], yet industry and academia continue to search for the magic bullet cure.

Keywords

Septic Shock Adult Respiratory Distress Syndrome Research Clinical Trial Sepsis Trial Sepsis Therapy 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Fisher CJ, Agosti JM, Opal SM, et al(1996) Treatment of septic shock with the tumor necrosis factor receptor: Fc fusion protein. N Engl J Med 334: 1697–1702Google Scholar
  2. 2.
    Bone RC, Fisher CJ Jr, Clemmer TP, Slotman GJ, Metz CA, Balk RA (1987) A controlled clinical trial of high-dose methylprednisolone in the treatment of severe sepsis and septic shock. N Engl J Med 317: 653–658PubMedCrossRefGoogle Scholar
  3. 3.
    Calandra T, Glauser MP, Schellekens J, Verhoef J (1988) Treatment of Gram-negative septic shock with human IgG antibody to Escherichia coli J5: A prospective, double-blind, randomized trial. J Infect Dis 158: 312–319Google Scholar
  4. 4.
    Greenman RL, Schein RM, Martin MA, et al(1991) A controlled clinical trial of E5 murine monoclonal IgM antibody to endotoxin in the treatment of Gram-negative sepsis. The XOMA Sepsis Study Group. JAMA 266: 1097–1102Google Scholar
  5. 5.
    Ziegler EJ, Fisher CJ Jr, Sprung CL, et al(1991) Treatment of Gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. A randomized, double-blind, placebo-controlled trial. The HA-1A Sepsis Study Group. N Engl J Med 324: 429–436PubMedCrossRefGoogle Scholar
  6. 6.
    Knaus WA, Harrel FE, Fisher CJ, et al(1993) The clinical evaluation of new drugs for sepsis: A prospective study design based on survival analysis. JAMA 270: 1233–1241Google Scholar
  7. 7.
    Fisher CJ, Slotman GJ, Opal SM, et al(1994) Initial evaluation of human recombinant interleukin-1 receptor antagonist in the treatment of sepsis syndrome: A randomized, open-label, placebo-controlled multicenter trial. Crit Care Med 22: 12–21Google Scholar
  8. 8.
    Van Dervort AL, Danner RL (1994) Antiendotoxin approaches to septic shock therapy (editorial). Crit Care Med 22: 539–540PubMedCrossRefGoogle Scholar
  9. 9.
    Bone RC, Fisher CJ, and the Methylprednisolone Severe Sepsis Study Group (1987) Early methylprednisolone treatment for septic syndrome and the adult respiratory distress syndrome. Chest 92: 1032–1036CrossRefGoogle Scholar
  10. 10.
    Weg JG, Balk RA, Tharratt S, et al(1994) Safety and potential efficacy of an aerosolized surfactant in human sepsis-induced adult respiratory distress syndrome. JAMA 272: 1433–1437PubMedCrossRefGoogle Scholar
  11. 11.
    Luce JM (1994) Introduction of new technology into critical care practice: A history of HA-1A human monoclonal antibody against endotoxin. Grit Care Med 21: 1233–1241CrossRefGoogle Scholar
  12. 12.
    Sprung CL, Finch RG, Thijs LG, Glauser MP (1996) International sepsis trial ( INTERSEPT ): Role and impact of a Clinical Evaluation Committee. Crit Care Med 24: 1441–1447Google Scholar
  13. 13.
    Sibbald WJ, Vincent JL (1995) Round table conference on clinical trials for the treatment of sepsis. Crit Care Med 23: 394–399PubMedCrossRefGoogle Scholar
  14. 14.
    Doig GS, Rochon J (1995) Statistical considerations for the design of the optimal clinical trial. In: Vincent JL, Sibbald WJ (eds) Update in Intensive Care and Emergency Medicine Vol 19: Clinical Trials for the Treatment of Sepsis. Springer-Verlag, New York, pp 345–353Google Scholar
  15. 15.
    Spilker B, Cramer JA (1992) A frame of reference for patient recruitment issues. In: Spilker B, Cramer JA (eds) Patient Recruitment in Clinical Trials. Raven Press, New York, pp 3–23Google Scholar
  16. 16.
    Meinert CL (1986) Single versus multicenter trials. In: Meinert CL, Tonascia S (eds) Clinical Trials: Design, Conduct and Analysis. Oxford University Press, New York, pp 23–29Google Scholar
  17. 17.
    Pocock SJ (1983) The size of a clinical trial: Multicenter trials. In: Pocock SJ (ed) Clinical trials: A practical approach. John Wiley and Sons, Chichester, pp 123–142Google Scholar
  18. 18.
    Members of the American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference Committee (1992) Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 20: 864–874CrossRefGoogle Scholar
  19. 19.
    Sibbald WJ, Doig GS, Inman KJ (1995) Sepsis, SIRS and infection. Intensive Care Med 21: 299–301Google Scholar
  20. 20.
    Seip A, Connolly S, Laupacis A, et al(1990) Systems of logging exclusions in multicenter clinical trials. Society for Clinical Trials Annual Meeting, Toronto (Abst)Google Scholar
  21. 21.
    Meinert CL (1986) Essential design features of a control clinical trial. In: Meinert CL, Tonascia S (eds) Clinical Trials: Design, Conduct and Analysis. Oxford University Press, New York, pp 65–68Google Scholar
  22. 22.
    Kreger BE, Craven DE, McCabe WR (1980) Gram-negative bacteremia. Am J Med 68: 344–355PubMedCrossRefGoogle Scholar
  23. 23.
    Thijs LG (1995) Fluid therapy in septic shock. In: Vincent JL, Sibbald WJ (eds) Update in Intensive Care and Emergency Medicine Vol 19: Clinical Trials for the Treatment of Sepsis. Springer-Verlag, New York, pp 167–190Google Scholar
  24. 24.
    Cook DJ, Guyett GH, Laupacis A, Sackett DL (1992) Rules of evidence and clinical recommendations on the use of antithrombotic agents. Chest 102 (Suppl): 3055–3115Google Scholar
  25. 25.
    Cohen J, Carlet J, for the INTERSEPT Study Group (1996) INTERSEPT: An international, multicenter, placebo-controlled trial of monoclonal antibody to human tumor necrosis factor-a in patients with sepsis. Grit Care Med 24: 1431–1440Google Scholar
  26. 26.
    Bone RC, Balk RA, Fein AM, et al(1995) A second large controlled clinical study of E5, a monoclonal antibody to endotoxin: Results of a prospective, multicenter, randomized, controlled trial. Crit Care Med 23: 994–1006Google Scholar
  27. 27.
    Schedel I, Dreikhausen U, Nentwig B, et al(1991) Treatment of Gram-negative septic shock with an immunoglobulin preparation: A prospective, randomized clinical trial. Grit Care Med 19: 1104–1113Google Scholar
  28. 28.
    Dhainaut JA, Tenaillon A, Le Tulzo Y, et al(1994) Platelet activating factor receptor antagonist BN 52021 in the treatment of severe sepsis: A randomized, double-blind, placebo-controlled, multicenter clinical trial. Crit Care Med 22: 1720–1728Google Scholar
  29. 29.
    Fisher CJ, Agosti JM, Opal SM, et al(1996) Treatment of septic shock with the tumor necrosis factor receptor: Fc fusion protein. N Engl J Med 334: 1697–1702Google Scholar
  30. 30.
    Greenberg RN, Wilson KM, Kunz Ay, et al(1992) Observations using antiendotoxin antibody (E5) as adjuvant therapy in humans with suspected, serious, Gram-negative sepsis. Crit Care Med 20: 730–735Google Scholar
  31. 31.
    Abraham E,Wunderink R, Silverman H, et al(1995) Efficacy and safety of monoclonal antibody to human tumor necrosis factor a in patients with sepsis syndrome. A randomized, controlled, double-blind, multicenter clinical trial. JAMA 273: 934–941Google Scholar
  32. 32.
    McCloskey RV, Straube RC, Sanders C, et al(1994) Treatment of septic shock with human monoclonal antibody HA-1A. Ann Intern Med 121: 1–5PubMedGoogle Scholar
  33. 33.
    Fisher CJ, Dhainaut JA, Opal SM, et al(1994) Recombinant human interleukin-1 receptor antagonist in the treatment of patients with sepsis syndrome. Results from a randomized, double-blind, placebo-controlled trial. JAMA 271: 1836–1843Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1997

Authors and Affiliations

  • D. M. Foster
  • G. S. Doig

There are no affiliations available

Personalised recommendations